InvestorsHub Logo
Followers 3
Posts 190
Boards Moderated 0
Alias Born 05/16/2013

Re: None

Friday, 03/25/2016 11:40:27 AM

Friday, March 25, 2016 11:40:27 AM

Post# of 429471
Pressure building for additional partnerships?

With all the increasing interest in Vascepa/EPA for currently off-label conditions (most recently evidenced by the study for Alzheimer's), it seems likely that interest by major pharma companies is increasing every month.

Evidence to suggest AMRN's interest in additional partnerships - even for off-label uses include:

Changes in AMARIN's website language
Recent high-level hiring
1A settlement language allowing an opening for additional off-label promotion

I think there's plenty of evidence to suggest that AMRN is contemplating additional partnerships - since buyout offers would be entirely premature at this point.

Looking forward to some increase in prescriptions, as well. I finally got a prescription two months ago, and will have blood work re-done in another month. Looking forward to sharing good results.

Hang in there, and enjoy the Easter weekend!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News